Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program on July 28, 2026 anti-TSHR centanafadine Drug Enforcement Administration NDSRI Otsuka reverse merger SIMTRIYO Thyroid associated opthalmopathies United States Food and Drug Administration Vyne yarrow flower extract YARW YB-101 +
FDA Approves Otsuka's Tool SIMTRIYO on July 27, 2026 Approved Attention deficit hyperactivity disorder centanafadine Clinical Nurse Specialists Drug Enforcement Administration NDSRI Otsuka SIMTRIYO Stimulant United States Food and Drug Administration +